Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

This study has been completed.
Information provided by:
National Institute on Alcohol Abuse and Alcoholism (NIAAA) Identifier:
First received: May 25, 2006
Last updated: April 7, 2008
Last verified: April 2008

The two purposes of this study are

  1. to determine what effect the chronic and moderate/heavy drinking of alcoholic beverages has

    1. on the blood level of bupropion and chlorzoxazone and their major breakdown products in the blood and
    2. on the stimulant effect of bupropion and
  2. to determine what effect a normal and common (25% frequency) genetic variation of a specific liver enzyme (that breaks down bupropion) has

    1. on the blood levels of bupropion and its major breakdown products in the blood and
    2. on the stimulant effect of bupropion.

Two groups of volunteers will be recruited for this study:

  1. volunteers who drink moderate to heavy amounts of alcohol frequently and
  2. volunteers who usually do not drink alcohol.

Volunteers will NOT be asked to change their drinking (or nondrinking) habits during the study.

Condition Intervention
Alcohol Drinking
Smoking Cessation
Attention Deficit Disorder
Drug: Bupropion
Drug: Chlorzoxazone
Drug: Ethanol

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Human CYP2B6: Induction by Ethanol and Polymorphisms

Resource links provided by NLM:

Further study details as provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):

Primary Outcome Measures:
  • Agitation
  • Insomnia

Estimated Enrollment: 80
Study Start Date: December 2005
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adults who are 21 - 55 years of age.
  • Either 1) Moderate-to-heavy drinkers who drink on average more than 14 but less than 28 drinks per week; OR 2) adults who normally abstain from drinking alcohol.

Exclusion Criteria:

  • Participants who are currently taking prescription medications (including oral contraceptives)
  • Pregnancy
  • Body mass index (BMI) greater than 30
  • History of seizures or eating disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00330434

United States, Massachusetts
Tufts University School of Medicine
Boston, Massachusetts, United States, 02111
Sponsors and Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: David J. Greenblatt, MD Tufts University; Chair of Department of Pharmacology and Experimental Therapeutics, Sackler School
Principal Investigator: Michael H. Court, BVsc, PhD Tufts University, Department of Pharmacology and Experimental Therapeutics, Sackler School
  More Information

Publications: Identifier: NCT00330434     History of Changes
Other Study ID Numbers: NIAAAGRE15647
1F32AA015647-01A1 ( US NIH Grant/Contract Award Number )
Study First Received: May 25, 2006
Last Updated: April 7, 2008

Keywords provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):
Cytochrome P450 Enzyme
Tufts University

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Alcohol Drinking
Behavioral Symptoms
Drinking Behavior
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Muscle Relaxants, Central
Neuromuscular Agents
Peripheral Nervous System Agents
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants processed this record on May 25, 2017